Dalleur O, Sibille F X, Mouzon A, Vaillant F, Marien S, Spinewine A, Boland B
Clinical Pharmacy & Pharmacoepidemiology Research Group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium.
Groupe de Recherche en Gériatrie & Gérontologie, Institut de Recherche Santé et Société (IRSS), UCLouvain, Brussels, Belgium.
Eur Geriatr Med. 2025 Jun 17. doi: 10.1007/s41999-025-01214-y.
The STOPP/START criteria are aimed to be used by clinicians to perform medication review to optimize pharmacotherapy in older adults. The STOPP/START.version 3 (SS.v3) published in European Geriatric Medicine in 2023 updated and significantly extended the previous version. SS.v3 is more open to criticism for its poor usability in daily clinical practice. The present study aimed at contributing to SS.v3 by highlighting the new content of its criteria and by providing clinicians, students and researchers with a user-friendly presentation to facilitate medication review.
The SS.v3 criteria were reviewed by seven geriatricians and clinical pharmacists with expertise in pharmacotherapy in older adults. The 190 SS.v3 criteria were carefully compared to the 115 SS.v2 criteria in order to identify the new ones and those with clinically significant modifications. A single-entry table was developed for the medications (STOPP.v3) and the medical conditions (START.v3).
Among the 133 STOPP.v3 criteria, we identified 54 new (41%) and 25 modified (19%) ones. The 57 START.v3 criteria include 24 new (42%) and 17 modified (30%) ones. The single-entry table is a comprehensive presentation of SSv3 in 3 pages. It is systematically organized and upfront presents the medication for the STOPP criteria and the condition for the START criteria, enhancing its usability.
This work highlights many new and modified SS.v3 criteria that clinicians, students and researchers should be aware of. The single-entry table for STOPP medications and START clinical conditions may facilitate medication review for older adults in daily clinical practice.
STOPP/START标准旨在供临床医生用于进行药物审查,以优化老年人的药物治疗。2023年发表于《欧洲老年医学》的STOPP/START第3版(SS.v3)对先前版本进行了更新并大幅扩展。SS.v3因其在日常临床实践中的可用性差而更容易受到批评。本研究旨在通过突出其标准的新内容,并为临床医生、学生和研究人员提供便于用户使用的呈现方式以促进药物审查,从而为SS.v3做出贡献。
由七位在老年人药物治疗方面具有专业知识的老年病医生和临床药师对SS.v3标准进行审查。将190条SS.v3标准与115条SS.v2标准进行仔细比较,以确定新的标准以及有临床意义修改的标准。为药物(STOPP.v3)和医疗状况(START.v3)制定了单条目表格。
在133条STOPP.v3标准中,我们确定了54条新的(41%)和25条修改的(19%)标准。57条START.v3标准包括24条新的(42%)和17条修改的(30%)标准。单条目表格在3页中全面呈现了SSv3。它系统地组织,并预先列出了STOPP标准的药物和START标准的状况,提高了其可用性。
这项工作突出了许多临床医生、学生和研究人员应知晓的新的和修改的SS.v3标准。STOPP药物和START临床状况的单条目表格可能有助于在日常临床实践中对老年人进行药物审查。